Katy Antonopoulou has more than 25 years of experience in the fields of health communications, with particular expertise in public information and awareness, patient rights advocacy, collaboration with scientific and institutional stakeholders, and the development of public health initiatives.

She is President of the Hellenic League Against Rheumatism (ELEANA) and President of Sjögren Europe. She also serves as Secretary General of Pain Alliance Europe, the Hellenic Menopause Society (ELETEM), EOS SPANOPA and the KALYPSO Association.

Furthermore, she is Head of Communications at the AGORA Federation, the European umbrella organisation representing associations of people with rheumatic and musculoskeletal diseases in Southern Europe.

As a EULAR Patient Research Partner and a member of both the EULAR PARE Committee and the EULAR Advocacy Committee, she actively participates in European research programmes, working groups and initiatives promoting the meaningful involvement of patients in research, health policy and decision-making processes.

She also participates in several working groups of the European Patients’ Forum and the Global Remission Coalition, contributing to the development of positions and recommendations concerning patients’ rights, equitable access to healthcare and patient representation at the European level.

Katy is the General Director of Alpha Public Relations, a company specialising in health communications, medical and scientific events, strategic communications, and stakeholder and institutional relations. She is also a member of the International Public Relations Association (IPRA) and the Chartered Institute of Public Relations (CIPR).

Throughout her many years of engagement, she has remained firmly committed to empowering patients, improving access to high-quality healthcare services, building strong partnerships and amplifying the voices of people living with chronic conditions at both national and European levels.

With dedication, extensive experience and a clear vision, she aims to continue contributing to the further development of ELEANA, expanding the scope of its work and improving the quality of life of people living with rheumatic diseases.